ZEPP — Zepp Health Corporation

Summary of Zepp Health Corporation Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Increased by 78.5% year-over-year to $75.8 million, meeting the upper end of guidance.
• Gross Margin: Reported at 38.2% (39.4% excluding tariffs), down from 40.6% in Q3 2024, influenced by product mix and promotional activities.
• Operating Expenses: Adjusted operating expenses were $28.6 million, stable year-over-year and reduced as a percentage of sales.
• Cash Balance: Increased to $103 million from $95 million in Q2 2025, driven by improved working capital.
• Operational Milestone: Achieved operating breakeven, a significant improvement from an adjusted operating loss of $11.3 million in Q3 2024.

2. Strategic Updates and Business Highlights

• Product Launches: The flagship Amazfit T-Rex 3 Pro launched in September, well-received by users, particularly in the endurance outdoor community. Other products like Balance 2 and Helio Strap continued strong performance.
• Acquisition: Acquired core assets from Wild.AI, enhancing the Amazfit ecosystem with personalized coaching capabilities for female athletes.
• Brand Expansion: Strengthened brand equity through athlete partnerships and community initiatives, including new ambassadors in Japan.
• Ecosystem Development: Continued integration of Zepp OS and enhancements in AI-driven training insights.

3. Forward Guidance and Outlook

• Q4 Revenue Guidance: Expected to be between $82 million and $86 million, representing 38% to 45% year-over-year growth.
• Market Positioning: Confidence in sustained growth driven by a strong product pipeline and margin improvement initiatives, despite a challenging macroeconomic environment.

4. Bad News, Challenges, or Points of Concern

• Supply Constraints: Notable supply issues with the Helio Strap due to memory chip shortages and typhoon-related shipment delays.
• Gross Margin Pressure: Decline in gross margin attributed to pricing strategies for entry-level products and promotional discounts impacting profitability.
• Macroeconomic Factors: Ongoing tariff impacts and inflationary pressures affecting costs and operational strategies.

5. Notable Q&A Insights

• Supply Chain Issues: Management confirmed that supply constraints on the Helio Strap were primarily due to high demand and industry-wide memory chip shortages.
• Holiday Season Demand: Positive signals for holiday sales, with management being cautious in guidance to account for potential supply issues and competition.
• Channel Strategy: Emphasis on growing online presence while also planning to expand offline distribution once supply constraints are resolved.
• Product Pipeline: Assurance of continued product launches with a cadence of 2-3 new products each quarter, maintaining excitement for upcoming innovations.

This summary encapsulates the key elements from the earnings call, reflecting both the positive growth trajectory and the challenges faced by Zepp Health Corporation.